ArticleTranslational cancer research2026
Analysis of prognostic factors in ovarian clear cell carcinoma: a retrospective cohort study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian clear cell carcinoma (OCCC) is a rare histological subtype of ovarian cancer, often associated with endometrial lesions, and characterized by poor prognosis and a high propensity for recurrence and metastasis. This study aimed to investigate the clinical characteristics of patients with OCCC and identify prognostic factors. Methods: A retrospective analysis was conducted on patients diagnosed with OCCC at Fujian Cancer Hospital from January 2007 to December 2018. Inclusion criteria were as follows: (I) histologically confirmed pure OCCC; (II) surgical intervention; (III) standardized and completed postoperative follow-up. Exclusion criteria were as follows: (I) patients with recurrence or metastasis; (II) patients who did not receive treatment. Kaplan-Meier survival curves were used to estimate progression-free survival (PFS) and overall survival (OS). Clinical outcomes were further analyzed using Cox proportional hazards regression. Results: The median follow-up duration for 102 patients was 89.62 months. At the time of the final follow-up, 44 patients had died, and 43 had experienced recurrence or metastasis. The 5-year OS and PFS rates were 59.2% and 50.0%, respectively. Univariate Cox regression analysis indicated that stage, concurrent endometriosis, chemotherapy, carbohydrate antigen 125 (CA-125) normalization, and CA-125 ≤20 U/mL were associated with both OS and PFS (P<0.05). Lymph node metastasis, platinum resistance, and venous thrombosis were only associated with OS (P<0.05). Multivariate analysis revealed that stage [hazard ratio (HR) =2.780, 95% confidence interval (CI): 1.265-6.110, P=0.01], chemotherapy (HR =0.211, 95% CI: 0.075-0.593, P=0.003), and platinum resistance (HR =8.233, 95% CI: 3.617-18.743, P<0.001) were independent prognostic factors for OS. Concurrent endometriosis (HR =0.385, 95% CI: 0.189-0.784, P=0.009) and stage (HR =4.507, 95% CI: 2.346-8.660, P<0.001) were independent prognostic factors for PFS. Conclusions: Stage, endometriosis, platinum resistance, and platinum-based chemotherapy are significant prognostic factors in OCCC. CA-125 levels, positive lymph nodes, and venous thrombosis are also associated with survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.